GlassScriptPhysician profile
Shivam G Patel
NPI 1285074013
$1,233.99
in general payments reported to CMS, 2019-2025
22 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.19 · 2020: $60.76 · 2021: $20.11 · 2022: $268 · 2023: $261 · 2024: $258 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $267.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Tandem Diabetes Care, INC. | $153.36 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $124.07 | 2023-2025 | Omnipod |
| Abbott Laboratories | $94.94 | 2022-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $79.52 | 2022-2025 | Jardiance, Zepbound |
| Sequel Med Tech, LLC | $63.04 | 2025 | Twiist |
| Amgen INC. | $57.89 | 2020-2025 | Repatha, Repatha |
| Recordati_rare_diseases_inc. | $49.78 | 2022-2024 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $42.53 | 2019-2022 | |
| Dexcom, INC. | $40.71 | 2022-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $32.34 | 2025 | |
| Radius Health, INC. | $31.29 | 2023 | Tymlos |
| Abbvie INC. | $27.90 | 2020-2025 | |
| Horizon Therapeutics Plc | $25.42 | 2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $22.76 | 2024 | Gvoke Hypopen |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $20.50 | 2023 | Tirosint, Licart |
| Eusa Pharma (US) LLC | $19.10 | 2022 | |
| Ascendis Pharma Endocrinology INC | $18.23 | 2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.22 | 2019 | |
| Almatica Pharma LLC | $17.70 | 2025 | Teriparatide |
| Cequr Corporation | $14.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivam Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.